Filing Flows › Health Care › ProPhase Labs (PRPH)
ProPhase Labs (PRPH) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 19, 2026 · ProPhase Labs (PRPH) Q2 2026 earnings results →
Q2 2026 Revenue down 19% year over year to $1.0M · 302¢ of every $1 of revenue lost · operating margin -261.6%
ProPhase Labs made $1.0M in Q2 2026 (-19% Y/Y). Operating margin -261.6%, net loss $3.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q2 2026, down 19% year over year and down 14% from the previous quarter.
Gross margin was 22.4%, down 36.5 points from Q2 2025. Operating costs exceeded revenue by $2.6M, an operating margin of -261.6%. Operating expenses fell 38% while revenue fell 19%. The quarter ended with a net loss of $3.1M, narrower than the previous quarter's $5.2M loss.
Operating cash flow was −$78K. Non-cash charges added back $1.0M of depreciation and amortization and $375K of share-based compensation. Working capital and other items added $1.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 19, 2026 | $1.0M | -19% | -261.6% | −$3.1M | −$78K |
| Q1 2026 | 10-Q | Jun 30, 2026 | $478K | -67% | -545.0% | −$5.2M | −$748K |
| Q4 2025 | 10-K | Jun 1, 2026 | $784K | -48% | -730.4% | −$7.4M | −$1.2M |
| Q3 2025 | 10-Q | Nov 19, 2025 | $883K | -38% | -539.5% | −$6.8M | −$3.5M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $1.2M | -17% | -312.3% | −$4.5M | −$247K |
| Q1 2025 | 10-Q | May 20, 2025 | $1.4M | -39% | -256.0% | $4.0M | −$3.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About ProPhase Labs
We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. (“Nebula”) and DNA Complete, Inc. ("DNA Complete").
In its own words, from its 10-K, filed Jun 1, 2026.
ProPhase Labs against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -19% against the peers' median +7%. Operating margin: -261.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PRPH ProPhase Labs | Q2 2026 | $1.0M | -19% | -261.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: ProPhase Labs 10-Q on SEC EDGAR · CIK 868278 · Pharmaceutical Preparations
13F: who owns PRPH and who is buying
More on PRPH
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results